Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

"Our new relationship with Sunnybrook Health Sciences Centre fits our strategy of fostering scientific exchange through external collaborations and will help us develop solutions for patients suffering from diabetic foot ulcers," said Ray Jupp, Vice President of sanofi-aventis' Therapeutic Strategy Unit, Fibrosis and Wound Repair.

The Fibrosis and Wound Repair unit is one of five Therapeutic Strategy Units created as part of sanofi-aventis' new R&D model. Three of these units cover major pathophysiology areas where there is significant unmet medical need: immuno-inflammatory disorders, infectious disease and fibrosis and wound repair.  The remaining two incorporate work in a challenging area of public health (the physiology of aging) and a high-potential geographic segment (Asia-Pacific region). The focus of the Therapeutic Strategy Units is to identify health solutions through pooling internal and external expertise and bring them to the clinic.

"Sunnybrook is dedicated to making discoveries and delivering them to patients—it's at the heart of all that we do," said Dr. Michael Julius, Vice President of Research at Sunnybrook. "Vasculotide, invented by senior scientist Dr. Dan Dumont and Dr. Paul Van Slyke at Sunnybrook Research Institute, is one of our most exciting discoveries. We are grateful that our commercialization agent MaRS Innovation identified sanofi-aventis as the ultimate partner, and we are committed to working with sanofi-aventis to help us develop vasculotide further."

Vasculotide is a synthetic peptide-based growth factor that targets Tie2, a receptor on specialized cells of the hematopoietic and vascular systems. Close to two decades ago, Dr. Dumont and his colleagues were the first to discover and detail the importance of Tie-2 and its role in the formation of blood vessels. Dumont and Van Slyke are now investigating the use of vasculotide for restoring vascular health and accelerating healing during wound repair. Vasculotide may provide a shortcut to the series of molecular activities involved in blood vessel growth that ultimately lead to wound closure, which may improve healing in patients. 

Under the terms of the agreement, sanofi-aventis has an exclusive worldwide option with predetermined upfront milestones and royalty payments with Sunnybrook to develop and commercialize vasculotide. The agreement was signed through Sunnybrook with the assistance of its commercialization agent MaRS Innovation. Financial terms of this agreement were not disclosed.

Source: Sanofi-aventis, MaRS Innovation, Sunnybrook Health Sciences Centre